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The introduction of a live attenuated Rotavirus vaccine (Rotarix®, GlaxoSmithKline Biologicals), to 22 
the UK’s child immunisation schedule in July 2013 has resulted in significant improvements in 23 
morbidity and healthcare usage by preventing rotavirus acute gastroenteritis (RAGE). In the UK 93% 24 
of eligible children complete their vaccination course with evidence of substantial herd protection 25 
(1). 26 
Although the main symptoms of rotavirus infection are gastrointestinal, it is also linked to central 27 
nervous system (CNS) pathology.  Studies from the United States (US) reported that up to 7% of 28 
infected children experience convulsions (2).  These may be febrile convulsions secondary to the 29 
pyrexia frequently associated with rotavirus,  or alternatively a direct effect of infection as rotavirus 30 
has been detected both in blood (3) and cerebrospinal fluid (4). Other putative mechanisms are 31 
indirect neurotoxicity, mediated through NSP4 enterotoxin (5) or nitric oxide (6). With rotavirus 32 
infection frequently gastro-intestinally asymptomatic (7), it may potentially be an under-recognised 33 
cause of CNS morbidity. 34 
In the US, Payne et al (8) performed a large retrospective cohort analysis of over 250,000 children 35 
from the CDC Vaccine Safety Datalink database and found an 18-21% risk reduction in rates of 36 
Emergency Department (ED) attendance or admission to hospital with childhood seizures in the year 37 
after rotavirus vaccination. A second study from the US using an insurance claim database of 1.8 38 
million children showed a 24% risk reduction of seizure hospitalisations persisting up to five years 39 
after vaccination (9). Both studies used Cox regression to analyse time to event, despite this 40 
technique assuming that the factors investigated have a constant impact on the hazard - or risk - 41 
over time (10). In Australia, Sheridan (11) used the screening method to compare the vaccination 42 
status of 2211 children attending the ED with febrile seizures to the general population and found 43 
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vaccine effectiveness of 35-38% for preventing presentation to the ED in the two years after 44 
vaccination. However ecological studies examining population-level benefit have found more 45 
variable strengths of association against seizure hospitalisation, ranging from 1 – 8% in an 46 
interrupted time series analysis (ITS) in the USA (12), a non-significant 16 – 34% trend in an 47 
uncontrolled before/after study design in North West Spain (13), to no association at all in South 48 
East Spain (14). 49 
 With such striking but inconsistent findings on one of the conditions most feared by parents (15), 50 
we felt it important to assess if the same effect could be detected in the UK.  We chose to examine 51 
population-level trends of childhood seizures regardless of individual characteristics, both before 52 
and after vaccine introduction, using an ITS analysis (16) to examine the vaccine’s effect on pooled 53 
aggregate risk of seizure. 54 
METHODS 55 
Data Sources 56 
Hospital Episodes Statistics (HES) is a centralised records system capturing all admissions and 57 
associated International Classification of Diseases (ICD-10) disease codes across National Health 58 
Service (NHS) Trusts in England. As all acute paediatric inpatient care occurs in NHS Trusts, with a 59 
financial incentive for accurately recorded admissions, these records can be effective in monitoring 60 
public health trends. 61 
We used HES to identify all admissions of children less than 3 years old with their first diagnosis of 62 
febrile or afebrile seizures (ICD-10 codes; G40*, epilepsy and recurrent seizures, G41*, status 63 
epilepticus, R56.0*, febrile convulsions) between April 2007 and March 2017. The previous studies 64 
have established a protective vaccine association in this age group, with some the largest impact in 65 
these infants (13), likely because they have the highest burden of rotavirus infection. As an analysis 66 
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of non-identifiable routinely collected data, following HRA guidance (17), our study did not require 67 
ethical review. 68 
Data analysis 69 
We fitted separate regression models for febrile and afebrile seizure counts; offset for English 70 
population changes using Office for National Statistics (ONS) mid-year estimates. Due to the 71 
immediate nature of vaccine introduction we tested for both a step and slope change in the rate of 72 
admissions before and after vaccine introduction. Age and year of admission were included in the 73 
model as predictor co-variates.  To avoid autocorrelation we analysed by whole year periods and 74 
assessed this using the Durbin-Watson test. In our secondary analyses we fitted separate models by 75 
age group to assess the effects of vaccination on both afebrile and febrile seizures, both of which 76 
could both be aetiologically relevant to rotavirus but have different age admission patterns. We also 77 
performed a further separate sub-analysis examining annual admissions in March - the height of 78 
Rotavirus season in England. As model residuals showed evidence of over-dispersion using the 79 
Poisson distribution, in the final analysis we used the negative binomial distribution. We corrected 80 
for multiple testing using the Holm method.  Data analysis was performed using R 3.4.1.(19) 81 
RESULTS 82 
During the 10-year study, the English population under 3 years old encompassed approximately 20 83 
million children (ONS). We identified 125,096 and 113,775 first-time admissions with afebrile and 84 
febrile seizures, respectively, across all hospitals in England, resulting in overall mean incidence rates 85 
of 623 and 568 /100,000 population. Rates of completed vaccine use in English eligible children 86 
remain consistently high, averaging 90% since introduction (18). England’s birth rate was also stable, 87 
with a mean of 672,216 ± SD 13,166 children born per year (ONS). 88 
The absolute numbers and rates of admission with non-febrile seizures remained broadly 89 
comparable (Table 1), even when analysis was restricted to different age groups (Figure 1). There 90 
 5 
 
was a decreasing trend in admissions with febrile convulsions, pre-dating the introduction of the 91 
rotavirus vaccine (Table 1). This trend is particularly well demonstrated for those aged 1-2 years 92 
(Figure 1), in whom we see the peak of presentation with febrile convulsions. 93 
Our primary outcome model did not detect a statistically significant reduction in annual admissions 94 
of under 3 year olds with either febrile, afebrile or all seizures in association with vaccine 95 
introduction and use (Table 2). Sub-analysis by age groups failed to show any significant relationship 96 
with vaccine use when adjusted for multiple testing in those aged 0-2 years old. A p value of 0.01 97 
(Table 2) was noted in those aged 2-3 when examining annual all-cause childhood seizure admissions 98 
in association with rotavirus vaccination. However in this subgroup, our ITS analysis is limited to only 99 
one year of post-vaccine data to compare to 9 years of pre-vaccine data and may not be truly 100 
significant. When the model was restricted to rates of admission in March, the peak of the rotavirus 101 
season in England, a reported p value of 0.01 was noted in relation to vaccine use and reduction of 102 
febrile seizures in those aged 2-3 years (Figure 2), alongside a p value of 0.002 in this age group for 103 
all-cause seizures (Table 2). As noted before, this age group is limited to only one year of post 104 
vaccine data and though corrected for multiple testing - is an analysis of a subset (by age group) in a 105 
subset (March only admissions). A planned secondary analysis looking at the primary research 106 
question but analysing all admissions with seizures, as opposed to first admission, had the same 107 
findings (data not shown). 108 
CONCLUSIONS 109 
Our study assessed the age-specific incidence rates of paediatric admissions with febrile and afebrile 110 
seizures for all English NHS Trusts across a 10-year period. Using ITS analysis, we did not detect a 111 
reduction in the rate of seizure admissions of <3 year olds associated with the mid-study 112 
introduction of rotavirus vaccine. We observed a reduction in the number of admissions with febrile 113 
seizures that pre-dated vaccine introduction and is likely to be due to evolving patterns of admission 114 
from pressures on hospital bed availability. This is consistent with the study from South East Spain 115 
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where rotavirus vaccination initially appeared negatively correlated with childhood seizure 116 
admissions, and all cause hospitalisation but accounting for confounders such as total hospitalisation 117 
rate there was no vaccine specific effect on seizures (14). They too attributed the decreasing trend in 118 
seizure hospitalisations to changes in admission policies from financial constraints following the 119 
economic crisis. When examining admissions in the peak of rotavirus season, we found a potential 120 
signal suggesting reduction in febrile seizures in children aged 2-3 years old. However with only one 121 
year of post-vaccine data in this age group we feel this is statistical artefact.  The peak age of febrile 122 
seizures is 18 months and in this age cohort we did not detect any effect despite younger children 123 
with seizure being more likely to be admitted. 124 
The strength of our study is its robust ecological size, comparing trends over a decade across the 125 
whole of the English paediatric population. Although an alternative study design, we analysed 80 to 126 
100-fold more seizures requiring medical attention than the aforementioned three cohort studies (8-127 
9, 14). These found varying strengths of direct protective association, with the lowest reported as a 128 
20% risk reduction in risk of seizures.  Despite the inherent flaws of an ecological study design, if 129 
such a significant effect existed in England we believe our much larger study would have detected a 130 
signal, given that our vaccine uptake is also higher. Thus we argue that this is an important negative 131 
finding; if a protective association of the monovalent vaccine cannot be detected at such this 132 
population level then the effect is unlikely to be clinically, or economically, significant. 133 
 134 
A major limitation of our study is that our data source only recorded paediatric hospital admissions 135 
and did not capture ED attendances. We were not able to examine whether vaccine effect can be 136 
found in presentations of convulsions to the ED where more minor attendances may be discharged 137 
after a period of observation. Current national emergency datasets in England do not consistently 138 
record discharge diagnoses and so do not allow the same analyses.  Reassuringly both of the cohort 139 
 7 
 
studies (8,11) that examined this still reported a significant finding for their sub-analyses of only 140 
admitted patients. 141 
As the HES dataset is centrally anonymised, a further limitation of our study is that we were unable 142 
to independently assess the accuracy of ICD-10 coding.  However a seizure is a significant clinical 143 
event and is likely to be well recorded.  Given that hospitals are paid based on these records they are 144 
financially incentivised to maintain the accuracy of them, as such they are the standard inpatient 145 
dataset for the UK. 146 
Our study is unique by investigating this protective association in England, where the monovalent 147 
vaccine Rotarix® is used. Existing studies have been performed in domains and countries 148 
predominately using the pentavalent vaccine (RotaTeq®, Merck & Co.), excepting Spain where both 149 
have been used, though combined coverage only reaches 29-41% and Rotarix® was unavailable for 150 
several years.  One intriguing hypothesis for our findings is that the effect on seizures is specific to 151 
the pentavalent vaccine. 152 
Other explanations for our contrary findings could include a different underlying epidemiology of 153 
rotavirus infection. Incidence of RAGE-associated childhood seizures has not been well documented 154 
in England and perhaps compared to other countries we see less CNS involvement. We were also 155 
unable to consider differing patterns of other seizure-inducing infections, such as influenza. Of note, 156 
this may have affected previous studies and may explain why the reducing trend in seizure 157 
hospitalisation in those under five years of age, noted by Pringle et al in the US (12), did not reflect 158 
the biennial pattern of RAGE which has emerged, as would be expected if it was the result of direct 159 
vaccine benefit.  160 
To extend this work we are planning to collect data to perform a time series analysis of 161 
presentations to the ED with childhood seizures in England over the same period, obtaining ICD-10 162 
discharge diagnoses from individual hospital trusts through the PERUKI network (20). We aim to 163 
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capture whether a protective association of the monovalent vaccine can be found against less severe 164 
forms of childhood seizures, which do not require hospitalisation. With a well-defined introduction 165 
of this vaccine and high uptake levels, ecological changes in England remain important in attempting 166 
to define any putative protective effect of the rotavirus vaccine, where further scientific evidence is 167 
needed. 168 
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Figure 1: Afebrile and febrile annual first-time seizure admission rates by age. 241 
Shaded area represents period vaccine available for age cohort. P value denotes effect of vaccine 242 




Figure 2: Afebrile and febrile first-time seizure admission rates in March of each year by age.  245 
Shaded area represents period vaccine available for age cohort. P value denotes effect of vaccine 246 
introduction on model. 247 
- 248 




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 
England Birth Rate 655357 672809 671058 687007 688120 694241 664517 661496 664399 663157 
Afebrile convulsions 
(n) 
11778 11514 11672 12595 12738 12788 12906 12923 13147 13035 
Rate / 100,000 
619 586 584 620 623 618 631 640 661 655 
Febrile convulsions 
(n) 
13111 13597 11705 11987 11267 11409 10725 10519 10174 9281 
Rate / 100,000 
689 692 585 590 551 551 524 521 511 467 
 250 
Table 1 Changes in birth rate & seizure admissions to inpatient English NHS Trusts over the period April 2007- March 2017 for children 251 
aged 0 to <3 years. Each year follows the English tax year, beginning in April and finishing the following March. The birth rate is as reported 252 











Children Aged <3 0.84 0.83 0.93 1 1 0.65 
 
Aged <12m 1.0 1.0 0.94 0.94 0.87 1 
Aged 1-2 1.0 0.85 0.8 0.80 0.94 1 
Aged 2-3 0.12 1.0 0.01 0.01 0.27 0.002 
 256 
Table 2 P values of evidence for statistical association of mid-study introduction of vaccine use and trends of childhood seizure 257 
hospitalizations in England from 2007-2017. P values are from separate regression model outputs analyzed in R. The primary model 258 
outcome is highlighted in italics. All subsequent sub-analyses have been corrected for multiple testing. The shaded table represents model 259 
outputs using admission data only collected in March, the peak of rotavirus seasonality. 260 
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